NACDS, APhA to hold two-day MTM summit
PHILADELPHIA The American Pharmacists Association and the National Association of Chain Drug Stores are presenting Sept. 19-20 a national conference that will showcase community pharmacist impact and successes in medication therapy management delivery. The summit will present information about current trends in the delivery of community pharmacy-based services and the issues associated with MTM delivery.
Among the goals of the conference, the NACDS stated, is to present innovations in MTM services delivery and business practices. The summit will also offer implementation tools to enable broad participation in MTM services delivery by pharmacists working in the community and will showcase successful programs and outcomes as potential models to payers, pharmacists, patients and other health care providers.
Attendees expected include pharmacists currently providing or interested in providing MTM services in their communities, pharmacy managers and administrators, prescription drug plan MTM administrators, self-insured employers, other third party payers and federal and state government agencies involved in MTM program development.
In addition, the conference will offer participants the opportunity to earn 8.0 contact hours (.80 CEU) of accredited continuing pharmacy education credit.
NACDS represents the nation’s leading retail chain pharmacies and suppliers, which operate more than 37,000 pharmacies, employ 114,000 pharmacists, fill more than 2.3 billion prescriptions yearly and have annual sales of nearly $700 billion.
APhA, founded in 1852, boasts more than 54,000 members, including practicing pharmacists, pharmaceutical scientists, pharmacy students and pharmacy technicians. The Association is a leader in providing professional information and education for pharmacists and an advocate for improved health of the American public through the provision of comprehensive pharmaceutical care.
Those interested in attending can visit <a title="www.nacds.org” href=”http://www.nacds.org/” />www.nacds.org for more information.
BlueCross/BlueShield of Oregon introduces new generics program
PORTLAND, Ore. Regence BlueCross BlueShield of Oregon has introduced a new program called Generics First Antidepressant Program, to help battle rising healthcare costs.
The program encourages the use of high-quality antidepressant generic medications. Since the company believes generics can meet the needs of most patients, brand-name drugs will require a prior authorization beginning in September. This though, does not necessarily mean that people already on brand-name medications will need a prior authorization.
Prices could result as follows, a 30-day supply of a generic could be $30 compared to a brand-name drug, which could cost $83. “These generics are a good value for members and are available without prior authorization,” said David Clark, vice president of Medical Services and Pharmacy for Regence.
AmerisourceBergen opens Orlando DC after deal with FDA
VALLEY FORGE, Pa. AmerisourceBergen Corp. announced that on August 25, 2007 the Drug Enforcement Administration reinstated AmerisourceBergen’s license for its Orlando Distribution Center to distribute controlled substances. The distribution center immediately resumed shipment of controlled substances to its customers.
The license was suspended in April 2007 because the DEA alleged that the distribution center had not maintained effective controls against diversion of controlled substances by retail Internet pharmacies. During the suspension, the company was able to provide the products to its customers from another distribution center.
Due to the suspension, AmerisourceBergen implemented an enhanced and more sophisticated order-monitoring program in all of its distribution centers starting July 1, 2007, The company has since passed several DEA inspections of the new program. AmerisourceBergen said that it expects the new order monitoring program to quickly become the industry standard, as it requires more rapid identification and daily reporting of orders that may indicate diversion of controlled substances, and, in some instances, may even require halting a shipment of orders to further investigate. The monitoring program also requires a more rigorous examination process before the delivery of controlled substances to newly signed customers.